Charles Schwab
TECX

Charles Schwab’s Tectonic Therapeutic TECX Stock Holding History

Charles Schwab’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Buy
30,438
+1,328
+5% +$39K ﹤0.01% 2996
2026
Q1 		$900K Sell
29,110
-3,351
-10% -$82.5K ﹤0.01% 2933
2025
Q4 		$677K Buy
32,461
+103
+0.3% +$1.91K ﹤0.01% 3061
2025
Q3 		$508K Sell
32,358
-7
-0% -$144 ﹤0.01% 3171
2025
Q2 		$643K Buy
+32,365
New +$656K ﹤0.01% 3043
2025
Q1 		– Sell
-4,711
Closed -$218K – 3517
2024
Q4 		$218K Buy
+4,711
New +$199K ﹤0.01% 3318
2023
Q1 		– Sell
-3,103
Closed -$26.5K – 3598
2022
Q4 		$26.5K Hold
3,103
– – ﹤0.01% 3471
2022
Q3 		$24K Hold
3,103
– – ﹤0.01% 3464
2022
Q2 		$35K Sell
3,103
-3,907
-56% -$46.1K ﹤0.01% 3449
2022
Q1 		$112K Sell
7,010
-1,114
-14% -$23K ﹤0.01% 3395
2021
Q4 		$376K Buy
8,124
+467
+6% +$26.8K ﹤0.01% 3239
2021
Q3 		$513K Sell
7,657
-13,043
-63% -$1.07M ﹤0.01% 3144
2021
Q2 		$2.21M Buy
20,700
+2,338
+13% +$277K ﹤0.01% 2680
2021
Q1 		$2.8M Sell
18,362
-52
-0.3% -$8.46K ﹤0.01% 2553
2020
Q4 		$3.08M Buy
18,414
+1,675
+10% +$298K ﹤0.01% 2452
2020
Q3 		$2.62M Buy
16,739
+1,601
+11% +$323K ﹤0.01% 2398
2020
Q2 		$3.17M Buy
15,138
+2,521
+20% +$519K ﹤0.01% 2252
2020
Q1 		$2.36M Buy
12,617
+1,654
+15% +$390K ﹤0.01% 2205
2019
Q4 		$2.65M Buy
10,963
+40
+0.4% +$7.71K ﹤0.01% 2330
2019
Q3 		$1.85M Buy
10,923
+6,162
+129% +$1.4M ﹤0.01% 2401
2019
Q2 		$929K Buy
4,761
+1,073
+29% +$231K ﹤0.01% 2598
2019
Q1 		$976K Buy
3,688
+957
+35% +$175K ﹤0.01% 2561
2018
Q4 		$546K Sell
2,731
-55
-2% -$16.8K ﹤0.01% 2735
2018
Q3 		$1.74M Buy
+2,786
New +$1.24M ﹤0.01% 2471

Other funds holding TECX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Charles Schwab's TECX Position: Q2 2026 in Review

Charles Schwab increased its Tectonic Therapeutic (TECX) stake by 4.6% in Q2 2026, buying an estimated $39K and bringing the position to 30,438 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Charles Schwab first reported a position in TECX in Q3 2018 and has held it in 24 quarters since. The position peaked at $3.17M in Q2 2020. 123 funds tracked by Wall St. Rank hold TECX as of Q2 2026.

  • Charles Schwab held 30,438 shares of Tectonic Therapeutic worth $1.05M as of Q2 2026.
  • Charles Schwab bought 1,328 Tectonic Therapeutic shares in Q2 2026, an estimated $39K.
  • Tectonic Therapeutic made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2996 holding.
  • Charles Schwab first reported a position in Tectonic Therapeutic in Q3 2018 and has held it in 24 quarters since.
  • Charles Schwab's Tectonic Therapeutic position peaked at $3.17M in Q2 2020.
  • 123 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.